

SAE classified by organ system

Number of patients with SAEs reported within the first 10 weeks after therapy start by SOC and PT (SAF)

Number of subjects with at least one such event	Eltrombopag N=36		Placebo N=41		Total N=77	
	N	%	N	%	N	%
Total	3	8.3	5	12.2	8	10.4
Infections and infestations	0	0.0	3	7.3	3	3.9
Appendicitis	0	0.0	1	2.4	1	1.3
Meningitis	0	0.0	1	2.4	1	1.3
Pneumonia	0	0.0	1	2.4	1	1.3
General disorders and administration site conditions	1	2.8	1	2.4	2	2.6
Pyrexia	1	2.8	0	0.0	1	1.3
Fatigue	0	0.0	1	2.4	1	1.3
Blood and lymphatic system disorders	1	2.8	0	0.0	1	1.3
Anemia	1	2.8	0	0.0	1	1.3
Eye disorders	1	2.8	0	0.0	1	1.3
Visual impairment	1	2.8	0	0.0	1	1.3
Gastrointestinal disorders	1	2.8	0	0.0	1	1.3
Abdominal pain	1	2.8	0	0.0	1	1.3
Metabolism and nutrition disorders	0	0.0	1	2.4	1	1.3
Hyperkalemia	0	0.0	1	2.4	1	1.3
Nervous system disorders	0	0.0	1	2.4	1	1.3
Syncope	0	0.0	1	2.4	1	1.3
Surgical and medical procedures	0	0.0	1	2.4	1	1.3
Tooth extraction	0	0.0	1	2.4	1	1.3

Number of subjects with at least one such event	Eltrombopag N=36		Placebo N=41		Total N=77	
	N	%	N	%	N	%
Total	4	11.1	4	9.8	8	10.4
Investigations	0	0.0	1	2.4	1	1.3
Blood bilirubin increased	0	0.0	1	2.4	1	1.3
Nervous system disorders	0	0.0	2	4.9	2	2.6
Cerebral venous thrombosis	0	0.0	1	2.4	1	1.3
Syncope	0	0.0	1	2.4	1	1.3
Blood and lymphatic system disorders	1	2.8	1	2.4	2	2.6
Hemolysis	1	2.8	0	0.0	1	1.3
Anemia	0	0.0	1	2.4	1	1.3
Cardiac disorders	1	2.8	0	0.0	1	1.3
Myocardial infarction	1	2.8	0	0.0	1	1.3
General disorders and administration site conditions	1	2.8	0	0.0	1	1.3
Condition aggravated	1	2.8	0	0.0	1	1.3
Infections and infestations	1	2.8	0	0.0	1	1.3
COVID-19 pneumonia	1	2.8	0	0.0	1	1.3
Injury, poisoning and procedural complications	0	0.0	1	2.4	1	1.3
Subcutaneous hematoma	0	0.0	1	2.4	1	1.3